Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Rapport Therapeutics | 2025 | Post-IPO Equity | Undisclosed | Boston |
| Pepgen | 2025 | Post-IPO Equity | Undisclosed | Oxford |
| Satellos Bioscience | 2025 | Post-IPO Equity | Undisclosed | Toronto |
| Willow | 2022 | Series D | Undisclosed | Mountain View |
| HilleVax | 2023 | Post-IPO Equity | Undisclosed | Boston |
| Forge Biologics | 2022 | Series C | Undisclosed | Grove City |
| Amylyx Pharmaceuticals | 2025 | Post-IPO Equity | Undisclosed | Cambridge |
| IDEAYA Biosciences | 2026 | Post-IPO Equity | Undisclosed | South San Francisco |
| Pyxis Oncology | 2026 | Post-IPO Equity | Undisclosed | Boston |
| Blueprint Medicines | 2022 | Post-IPO Equity | Undisclosed | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Rapport Therapeutics | Post-IPO Equity | Undisclosed | Boston, United States |
| 2 | Pepgen | Post-IPO Equity | Undisclosed | Oxford, United Kingdom |
| 3 | Satellos Bioscience | Post-IPO Equity | Undisclosed | Toronto, Canada |
| 4 | Willow | Series D | Undisclosed | Mountain View, United States |
| 5 | HilleVax | Post-IPO Equity | Undisclosed | Boston, United States |
| 6 | Forge Biologics | Series C | Undisclosed | Grove City, United States |
| 7 | Amylyx Pharmaceuticals | Post-IPO Equity | Undisclosed | Cambridge, United States |
| 8 | IDEAYA Biosciences | Post-IPO Equity | Undisclosed | South San Francisco, United States |
| 9 | Pyxis Oncology | Post-IPO Equity | Undisclosed | Boston, United States |
| 10 | Blueprint Medicines | Post-IPO Equity | Undisclosed | Cambridge, United States |
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
PepGen is empowering nucleic acid therapeutics to go the distance.
Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration.
Willow is a women's healthcare company that develops pumping bras and breast pumps for women.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Forge Biologics is a gene therapy development engine, enabling access to life changing gene therapy programs.
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
IDEAYA Biosciences is an oncology-focused biotechnology company that develops therapeutics for patients with genetically-defined cancers.
Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Orchestra BioMed is a biomedical innovation company that provides high-impact solutions for large unmet needs in procedure-based medicine.
A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
ByHeart is a baby nutrition company with FDA-registered infant formula.
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Forte Biosciences is a biotechnology company that focuses on dermatology.
Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.
Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.
Surf Bio develops therapeutic solutions for diabetes, oncology, infectious diseases, and gene therapy.
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Perceptive Advisors has invested in 168 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 23 different industry categories.
Among tracked funding rounds, Solid Biosciences received $240.0M in a Post Ipo Equity round. Perceptive Advisors's total known invested capital is $9.5B.
Perceptive Advisors's average investment size is $101.5M across its portfolio of 168 companies.
Recent Perceptive Advisors portfolio additions include Rapport Therapeutics, Pepgen, Satellos Bioscience, Willow, HilleVax. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors